Blood clotting disorders among AstraZeneca COVID-19 vaccine recipients

Embargoed until: Publicly released: 2021-04-10 02:00

International

What does this mean?

Jump to: MultimediaAttachmentsExpert Reaction

Two studies detail the cases of people who developed blood clotting problems after receiving the AstraZeneca COVID-19 vaccine. The first study, by Austrian and German researchers, assessed 11 cases in Germany. Nine of the 11 cases were women, and their average age was 36. Of the 11 cases, nine had blood clots in the brain, three had blood clots in their gastrointestinal system, three had blood clots in their lungs, and four had blood clots elsewhere. The patients started to develop blood clotting issues between five and 16 days after getting the jab, the researchers say. Of these patients, six died. The second study, by Norwegian researchers, assessed five cases among healthcare workers aged between 32 and 54 years, which developed between seven and ten days after receiving the jab. The authors of both studies stress the rarity of blood clotting issues - the authors of the Norwegian study point out that the five cases they looked at occurred among 130,000 people who received the vaccine.